Cosibelimab治疗晚期皮肤鳞状细胞癌的长期疗效与安全性
该关键性开放标签研究评估了Cosibelimab-ipdl(一种PD-L1阻断抗体)在转移性或局部晚期皮肤鳞状细胞癌患者中的长期疗效与安全性。中位随访≥2年结果显示,转移性队列客观缓解率50.0%(完全缓解12.8%),局部晚期队列客观缓解率54.8%(完全缓解25.8%),缓解持续时间持久,免疫相关不良事件发生率27.6%,≥3级仅3.6%。
要点
- 转移性CSCC队列ORR 50.0%,CR 12.8%,24个月DOR率72.1%。
- 局部晚期CSCC队列ORR 54.8%,CR 25.8%,24个月DOR率80.2%。
- 免疫相关不良事件率27.6%,≥3级3.6%,无≥4级事件。
核心结论
- Cosibelimab在晚期皮肤鳞状细胞癌中显示出稳健且持久的客观缓解率,完全缓解率随随访增加,严重免疫相关不良事件发生率低。
研究设计与样本
- 关键性开放标签研究,转移性CSCC队列n=78,局部晚期CSCC队列n=31;给药方案为静脉注射Cosibelimab 800 mg每2周(两队列)或1200 mg每3周(转移性队列)。
主要发现
- 转移性CSCC队列中位随访29.3个月,ORR 50.0%(CR 12.8%),中位DOR未达到,估计24个月DOR率72.1%。
- 局部晚期CSCC队列中位随访24.1个月,ORR 54.8%(CR 25.8%),中位DOR未达到,估计24个月DOR率80.2%。
- 免疫相关不良事件发生率为27.6%,3级事件占3.6%,无≥4级事件。
关键数值与推荐
- 免疫相关不良事件:总发生率27.6%,3级3.6%,≥4级0%。
临床怎么用
- Cosibelimab已获FDA批准用于不适合根治性手术或放疗的转移性或局部晚期皮肤鳞状细胞癌成人患者。
- 长期随访数据支持其作为该人群的治疗选择,需关注免疫相关不良事件但严重事件率较低。
局限性
- 研究为非随机设计。
- 生物标志物分析有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cosibelimab-ipdl, a high-affinity, programmed death-ligand 1-blocking antibody, is approved by the US Food and Drug Administration for treatment of adults with metastatic cutaneous squamous cell carcinoma (mCSCC) or locally advanced CSCC (laCSCC) who are not candidates for curative surgery or radiation. OBJECTIVE: To report long-term efficacy and safety outcomes from a pivotal study of cosibelimab in mCSCC or laCSCC. METHODS: Patients received intravenous cosibelimab 800 mg every 2 weeks (mCSCC and laCSCC cohorts) or 1200 mg every 3 weeks (mCSCC cohort). The primary endpoint was objective response rate (ORR). Secondary endpoints included duration of response (DOR) and safety. RESULTS: With a median follow-up duration of 29.3 months for the mCSCC cohort (n = 78), ORR was 50.0% (complete response [CR], 12.8%), median DOR was not reached, and estimated 24-month DOR was 72.1%. With a median follow-up duration of 24.1 months for the laCSCC cohort (n = 31), ORR was 54.8% (CR, 25.8%), median DOR was not reached, and the estimated 24-month DOR was 80.2%. Immune-related adverse event rate was 27.6%; 3.6% grade 3, no grade ≥4 events. LIMITATIONS: Nonrandomized; limited biomarker analysis. CONCLUSION: Cosibelimab demonstrated robust and durable ORRs with increasing CR rates in advanced CSCC and low rates of severe immune-related adverse events.
引用
- Ruiz ES, Muñoz-Couselo E, Montaudié H, et al. Efficacy and safety of cosibelimab in advanced cutaneous squamous cell carcinoma: Results from a Pivotal Open-label Study with a median follow-up of ≥2 years. J Am Acad Dermatol. 2025. PMID: 41055628. doi:10.1016/j.jaad.2025.09.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。